Cerebrolysin
moderate riskAlso: FPF-1070 · EVER Neuro Pharma Cerebrolysin · Porcine Brain Hydrolysate
Cerebrolysin is a neuropeptide mixture derived from porcine (pig) brain tissue, containing low-molecular-weight peptide fragments and free amino acids. It has been approved and used clinically for Alzheimer's disease, vascular dementia, and traumatic brain injury in Europe, Russia, China, and other countries for decades. Mechanism involves neurotrophic factor-like activity and neuroprotection. Not FDA-approved; considered an unapproved drug in the US.
Reported Benefits
Alzheimer's disease
Multiple RCTs (primarily European and Asian) show modest cognitive improvement on ADAS-cog and MMSE scales. A 2020 Cochrane review found some evidence of benefit but rated quality as low-to-moderate.
Vascular dementia
Studies from Russia and China show functional and cognitive improvement; methodological heterogeneity limits conclusions.
Traumatic brain injury / stroke recovery
Several RCTs support improved neurological outcomes post-TBI and ischemic stroke; effect sizes are modest and study quality varies.
Neuroprotection
Preclinical models consistently show reduction in excitotoxicity, oxidative stress, and apoptosis in neuronal tissue.
Mechanism of Action
Cerebrolysin's peptide fragments exhibit neurotrophic factor-like activity, mimicking BDNF, NGF, and GDNF effects on neuronal survival, differentiation, and synaptic plasticity. Proposed mechanisms include reduction of amyloid-beta aggregation, inhibition of apoptotic cascades (caspase-3), attenuation of glutamate-mediated excitotoxicity, and promotion of neurogenesis in the hippocampus. The mixture's small molecular size allows blood-brain barrier penetration.
Key Clinical Studies
Gauthier S et al. (2015)
Randomized, double-blind, placebo-controlled · 265
Cerebrolysin 30 mL/day showed significant improvement on ADAS-cog+ in mild-to-moderate Alzheimer's at 24 weeks
Álvarez XA et al. (2011)
Randomized, double-blind, placebo-controlled · 139
Cerebrolysin plus donepezil showed greater ADAS-cog improvement than donepezil alone in Alzheimer's patients
Muresanu DF et al. (2016)
Randomized, double-blind, placebo-controlled · 208
Cerebrolysin improved neurological recovery in moderate-to-severe TBI at 90 days
Overview
Cerebrolysin is one of the most-studied neuropeptide preparations in the world — just not in the United States. Derived from purified porcine brain protein, it is a proprietary mixture of low-molecular-weight peptides and free amino acids that has been used clinically in Europe, Russia, China, and parts of Latin America for over 50 years. In those markets, it holds regulatory approval for Alzheimer’s disease, vascular dementia, stroke, and traumatic brain injury. In the US, it is not FDA-approved and is not available through licensed compounding pharmacies.
Evidence
The clinical trial record for Cerebrolysin is real but complicated. Over 30 randomized controlled trials have been conducted — a higher bar than most research peptides. A 2020 Cochrane systematic review concluded there was some evidence of benefit in Alzheimer’s disease, particularly on cognitive measures, but rated the quality of evidence as low-to-moderate due to small sample sizes, short durations, and geographic concentration of trials in Eastern Europe and Asia. The trials that do exist are more rigorous than most peptide research, but they lack the scale and diversity of typical FDA approval packages.
Regulatory Status / Clinical Use
Cerebrolysin is approved by the EMA-recognized national agencies in Austria (its country of origin, manufactured by EVER Neuro Pharma), as well as Russia, China, Ukraine, and several other countries. In the US, it is considered an unapproved drug. Practitioners who use it obtain it through international sources — it is not available through domestic 503A or 503B compounding. This creates real regulatory and supply chain risk for US-based practitioners.
Bottom Line
Cerebrolysin occupies a unique position: it has more clinical evidence than nearly any other research peptide, a decades-long safety record in clinical settings, and regulatory approval in major non-US markets. The barrier is regulatory, not scientific. For practitioners in jurisdictions where it is approved, it remains a first-line neuropeptide option for dementia and TBI. In the US, it is a research compound with meaningful evidence and meaningful regulatory risk.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
RestrictedNot FDA-approved; not 503A-listed; available in Europe/Asia as prescription drug; restricted/unapproved in US
Safety Profile
Side Effects
- •Nausea
- •Dizziness
- •Agitation (rare)
- •Injection site reactions
- •Headache
- •Sweating
- •Allergic reactions (rare; porcine origin)
Contraindications
- •Pork/porcine protein allergy
- •Epilepsy (may lower seizure threshold)
- •Renal failure
- •Acute psychiatric episodes
Drug Interactions
- •MAO inhibitors
- •Antidepressants (serotonergic — additive effect)
- •Antiepileptics (interaction uncertain)
Primary Uses
Related Peptides
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Cerebrolysin?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →